Phio Pharmaceuticals Reports Exciting Progress in Cancer Treatment Research
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has made significant strides in the development of its lead clinical candidate, PH-762, targeting cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma. In a recent update, the company outlined its achievements in the first quarter of 2026 following the completion of their multi-center Phase 1b clinical trial. This localized approach to immunotherapy leverages proprietary INTASYL® gene silencing technology aimed at offering new hope for cancer patients while minimizing harmful side effects typically associated with systemic treatments.
PH-762's Clinical Trial Shows Promise
In March 2026, the results from the Phase 1b clinical trial were presented at the American Academy of Dermatology (AAD) Annual Meeting. The trial involved administering PH-762 through intratumoral injections, targeting the PD-1 pathway to modulate immune responses within the tumor microenvironment. The results were encouraging, with 65% of patients experiencing significant pathological responses. Notably, among those treated, 45% achieved complete pathological response, indicating a serious advancement in efficacy compared to previous therapies.
Balancing Efficacy with Safety
One of the most significant findings from the trial is PH-762's safety profile. Unlike traditional systemic therapies that often cause immune-related adverse events, PH-762 demonstrated no serious adverse events or dose-limiting toxicities. This localized delivery mechanism is designed to focus treatment directly where it’s needed, potentially reducing systemic toxicity. As stated by Dr. Mary Spellman, one of the trial's lead investigators, the approach aims to bring "immune balance to treat tumor cells," suggesting that this could pave the way for safer treatment strategies.
Financial Health Supporting Ongoing Research
Phio Pharmaceuticals has strengthened its financial position through strategic equity financings, securing approximately $23.7 million in net proceeds during 2025. This financial backing allows the company to extend its operational runway into the first half of 2027, supporting continued clinical development of PH-762 and related strategic initiatives.
Next Steps and FDA Interactions
Looking ahead, Phio is preparing for an upcoming interface with the FDA that will outline the next steps for advancing PH-762’s development program. The submission is scheduled for the second quarter of 2026 and aims to clarify the design of future studies and ensure that the promising results can translate into effective treatments for cancer patients.
Potential Implications for Patients
The development of PH-762 represents a significant advancement in immunotherapy for skin cancers, addressing the acute need for effective treatments that do not compromise patient safety. With the ongoing evaluation of its efficacy and safety, there is cautious optimism for the drug's potential to transform the landscape of cancer treatment.
Final Thoughts
As Phio Pharmaceuticals navigates this critical phase of development, the biotechnology community will be watching closely. Successful trials could bring a breakthrough not just for those suffering from cutaneous carcinomas, but also inspire further innovations in cancer therapies. Supporters and stakeholders should follow the company's progress as it approaches a pivotal juncture in its roadmap to bringing PH-762 to market.
Write A Comment